Name: 美國與禮來公司就潛在的COVID-19藥物達成協議 (U.S., Eli Lilly strike deal for potential COVID-19 drug)
Uploaded: 2020-10-28T19:41:41.000Z
Duration: 1 min 21 s

情態助動詞 B1

the US government reached a deal for nearly one million doses of drugmaker Eli Lilly's experimental Koven 19 antibody treatment, which may cost over $1 billion.

美國政府達成協議，購買近100萬劑製藥商禮來的實驗性Koven 19抗體療法，成本可能超過10億美元。

The pharma giant set on Wednesday once it receives an emergency use authorization from the Food and Drug Administration, it will start delivering 300,000 doses of the treatment within two months.

該製藥巨頭週三設定，一旦收到食品和藥物管理局的緊急使用授權，它將在兩個月內開始交付30萬劑量的治療。

S government will pay $375 million for that first delivery after that, U.

斯政府將支付3.75億美元的首期交付，此後，U。

S Department of Health and Human Services said the government has an option to buy an additional 650,000 vials for more than $800 million.

S衛生和人類服務部表示，政府有選擇以超過8億美元的價格購買額外的65萬個小瓶。

Three agreement with the US came days after the company said the drug failed to show benefits in hospitalized patients.

與美國達成的三項協議是在該公司表示該藥物未能在住院患者中顯示出好處之後幾天。

But Eli Lilly said it remains confident it's treatment can prevent the progression of disease when it has started earlier.

但禮來表示，它仍然有信心它的治療可以防止疾病的發展，當它更早地開始。

There are also questions about the company's facilities.

S drug inspectors uncovered serious quality control problems at an Eli Lilly plant that is ramping up to make its anti body therapy.

S藥品檢查員在禮來工廠發現了嚴重的品質控制問題，該工廠正在加緊製造其抗身體療法。

The drugmaker said the issues raised by US regulators after the inspection do not affect the quality or safety of the treatment.

該藥廠表示，美國監管機構在檢查後提出的問題並不影響治療的品質和安全性。

 Eli Lilly applied for an FDA emergency use authorization of the drug to treat mild to moderate Koven 19 patients earlier this month. 

禮來公司本月早些時候申請了FDA的緊急使用授權，該藥用於治療輕度至中度科文19患者。